IMMUNOVANT INC's ticker is IMVT and the CUSIP is 45258J102. A total of 117 filers reported holding IMMUNOVANT INC in Q3 2020. The put-call ratio across all filers is - and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $239,290,475 | +130.7% | 6,233,146 | +14.0% | 0.01% | +200.0% |
| Q2 2023 | $103,739,646 | +30.0% | 5,468,616 | +6.3% | 0.00% | 0.0% |
| Q1 2023 | $79,778,926 | -11.3% | 5,143,709 | +1.5% | 0.00% | 0.0% |
| Q4 2022 | $89,976,862 | +303.1% | 5,069,119 | +26.7% | 0.00% | +100.0% |
| Q3 2022 | $22,322,000 | +43.1% | 4,000,450 | +0.0% | 0.00% | – |
| Q2 2022 | $15,597,000 | -24.8% | 3,999,493 | +6.2% | 0.00% | – |
| Q1 2022 | $20,750,000 | -36.5% | 3,765,713 | -1.8% | 0.00% | -100.0% |
| Q4 2021 | $32,667,000 | +0.3% | 3,834,119 | +2.3% | 0.00% | 0.0% |
| Q3 2021 | $32,581,000 | -23.0% | 3,749,286 | -6.3% | 0.00% | 0.0% |
| Q2 2021 | $42,288,000 | -34.0% | 4,000,697 | +0.1% | 0.00% | -50.0% |
| Q1 2021 | $64,107,000 | -64.2% | 3,996,720 | +3.0% | 0.00% | -60.0% |
| Q4 2020 | $179,150,000 | +60.1% | 3,878,549 | +21.9% | 0.01% | +25.0% |
| Q3 2020 | $111,927,000 | +172.0% | 3,180,644 | +88.2% | 0.00% | +300.0% |
| Q2 2020 | $41,155,000 | – | 1,690,114 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Alpine Global Management, LLC | 4,448,017 | $17,347,000 | 4.39% |
| Deep Track Capital, LP | 9,455,000 | $36,875,000 | 2.42% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 233 | $60,000,000 | 0.63% |
| Octagon Capital Advisors LP | 579,061 | $2,258,000 | 0.60% |
| Eventide Asset Management | 5,372,512 | $20,953,000 | 0.45% |
| WITTENBERG INVESTMENT MANAGEMENT, INC. | 174,000 | $679,000 | 0.29% |
| Frazier Life Sciences Management, L.P. | 585,759 | $2,284,000 | 0.22% |
| BCK CAPITAL MANAGEMENT LP | 54,293 | $212,000 | 0.16% |
| PLATINUM INVESTMENT MANAGEMENT LTD | 777,590 | $3,033,000 | 0.12% |
| Bridgefront Capital, LLC | 15,649 | $61,000 | 0.07% |